• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Activated NK Cell Injection Cell Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is a global leader in the development and optimization of allogeneic NK cell therapies. Our scientists are proud to offer activated NK cell injection cell development service, utilizing advanced allogeneic NK cell activation and expansion technologies. Our team of experts is dedicated to advancing the field of immunotherapy and providing cutting-edge solutions for researchers in need.

Activated NK Cell Injection Cell Development Process

Creative Biolabs offers a comprehensive allogeneic-activated NK cell development service, a groundbreaking service that leverages the power of NK cells for cancer research. The production of activated NK cells starts with isolating pure primary NK cells from the peripheral blood of healthy donors, guaranteeing a dependable and high-quality source material. The NK cells undergo a unique activation and expansion process. These cells are then collected and cryopreserved. Through careful cultivation and optimization of culture conditions, we can ensure the quality and functionality of these highly potent immune cells. Our process not only increases the number of NK cells but also enhances their cytotoxicity and anti-tumor capabilities, providing a powerful tool for combating a range of diseases.

Activated NK Cell Technology Platform

At Creative Biolabs, our allogeneic-activated NK cell platform combines cutting-edge activation and expansion technologies, advanced cryopreservation methods, efficient thawing techniques, and innovative modification strategies. This platform offers a promising off-the-shelf approach that can provide a readily available source of NK cells, making them ideal for the treatment of solid tumors.

• Our activation and expansion technologies enable the expansion of peripheral blood-derived NK cells by thousands-fold amplification to enhance their therapeutic potential. This process can generate thousands of doses from a single donor, ensuring scalability and efficiency in treatment production.
• Creative Biolabs incorporates state-of-the-art cryopreservation techniques to ensure the long-term stability of activated NK Cells. Our specialized cryopreservation methods allow the cells to be effectively frozen without compromising their functionality or potency. When it comes to thawing techniques, our experts have perfected the process to guarantee optimal cell recovery and viability post-thaw.
• Our service extends to modification techniques, including the integration of Chimeric Antigen Receptor (CAR) technology into NK Cells (CAR-NK). By engineering CAR-NK Cells, we enhance their specificity and potency in targeting cancer cells. This innovative approach maximizes the therapeutic potential of allogeneic NK cells, providing promise for personalized and precise cancer immunotherapy strategies.

Superiority of Activated NK Cells

• High purity of NK cells: Activated NK cells consist of NK cells with a 95% purity level.
• Larger production: Using our proprietary culturing technology, the NK cells are harvested with thousands-fold amplification.
• Enhanced antitumor activity: Activated NK cells exhibit enhanced cytotoxicity and improved antitumor activity.
• Improved immune activity: Activated NK cells exhibit abundant cytokine secretion.

Reference

1. Liu, Chuanling, et al. "Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity." Immunity, Inflammation and Disease 12.1 (2024): e1143.